[PDF][PDF] Antiviral agents for the treatment of COVID-19: Progress and challenges
M Singh, E de Wit - Cell Reports Medicine, 2022 - cell.com
The COVID-19 pandemic has seen clinical development and use of antiviral therapies at an
unprecedented speed. Antiviral therapies have greatly improved the clinical outcome in …
unprecedented speed. Antiviral therapies have greatly improved the clinical outcome in …
Covid-19: a comprehensive review of a formidable foe and the road ahead
A Hussain, S Yadav, V Hadda, TM Suri… - Expert review of …, 2020 - Taylor & Francis
ABSTRACT Introduction The Coronavirus disease-19 (COVID-19) caused by the novel beta
coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) started …
coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) started …
Treating COVID-19: are we missing out the window of opportunity?
J Sundararaj Stanleyraj, N Sethuraman… - Journal of …, 2021 - academic.oup.com
Severe COVID-19 is a biphasic illness, with an initial viral replication phase, followed by a
cascade of inflammatory events. Progression to severe disease is predominantly a function …
cascade of inflammatory events. Progression to severe disease is predominantly a function …
Pharmacotherapy in COVID-19; A narrative review for emergency providers
N Mehta, M Mazer-Amirshahi, N Alkindi… - The American journal of …, 2020 - Elsevier
Introduction The COVID-19 pandemic has been particularly challenging due to a lack of
established therapies and treatment guidelines. With the rapid transmission of disease, even …
established therapies and treatment guidelines. With the rapid transmission of disease, even …
[HTML][HTML] Emerging treatment strategies for COVID-19 infection
M Gavriatopoulou, I Ntanasis-Stathopoulos… - Clinical and …, 2021 - Springer
The new type of coronavirus (COVID-19), SARS-CoV-2 originated from Wuhan, China and
has led to a worldwide pandemic. COVID-19 is a novel emerging infectious disease caused …
has led to a worldwide pandemic. COVID-19 is a novel emerging infectious disease caused …
Treatments for COVID-19
HS Andrews, JD Herman… - Annual Review of …, 2024 - annualreviews.org
The treatment for COVID-19 has evolved rapidly since the start of the pandemic and now
consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir …
consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir …
[HTML][HTML] Precision therapeutic targets for COVID-19
ZA Krumm, GM Lloyd, CP Francis, LH Nasif… - Virology journal, 2021 - Springer
Beginning in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
emerged as a novel pathogen that causes coronavirus disease 2019 (COVID-19). SARS …
emerged as a novel pathogen that causes coronavirus disease 2019 (COVID-19). SARS …
[PDF][PDF] Therapeutic options for COVID-19: a review
R Pujari, MV Thommana, BR Mercedes, A Serwat - Cureus, 2020 - cureus.com
An acute respiratory disease caused by a novel coronavirus [severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV], the coronavirus …
syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV], the coronavirus …
COVID-19: Cause of death and medications
AL Urakov, NA Urakova - IP International Journal of Comprehensive and …, 2020 - elibrary.ru
It is shown that in patients with severe pneumonia with COVID-19, the lungs lose their
airiness, as pus and mucus completely fill the lumen of their Airways. Gas exchange in the …
airiness, as pus and mucus completely fill the lumen of their Airways. Gas exchange in the …
[HTML][HTML] Covid‐19: time for a paradigm change
FM Buonaguro, PA Ascierto, GD Morse… - Reviews in medical …, 2020 - ncbi.nlm.nih.gov
As of May 11, 2020, coronavirus disease 2019 (Covid-19) has been confirmed in 4 152 670
people worldwide, carrying a mortality of approximately 6.8%, 1 compared with a mortality …
people worldwide, carrying a mortality of approximately 6.8%, 1 compared with a mortality …